PL2247592T3 - Pirolopirazynowe inhibitory kinazy - Google Patents

Pirolopirazynowe inhibitory kinazy

Info

Publication number
PL2247592T3
PL2247592T3 PL09713736T PL09713736T PL2247592T3 PL 2247592 T3 PL2247592 T3 PL 2247592T3 PL 09713736 T PL09713736 T PL 09713736T PL 09713736 T PL09713736 T PL 09713736T PL 2247592 T3 PL2247592 T3 PL 2247592T3
Authority
PL
Poland
Prior art keywords
kinase inhibitors
pyrrolopyrazine
pyrrolopyrazine kinase
inhibitors
kinase
Prior art date
Application number
PL09713736T
Other languages
English (en)
Inventor
Joe Timothy Bamberg
Mark Bartlett
Bois Daisy Joe Du
Todd Richard Elworthy
Robert Than Hendricks
Johannes Cornelius Hermann
Rama K Kondru
Remy Lemoine
Yan Lou
Timothy D Owens
Jaehyeon Park
David Bernard Smith
Michael Soth
Hanbiao Yang
Calvin Wesley Yee
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2247592T3 publication Critical patent/PL2247592T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL09713736T 2008-02-25 2009-02-16 Pirolopirazynowe inhibitory kinazy PL2247592T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3103508P 2008-02-25 2008-02-25
US20572409P 2009-01-22 2009-01-22
EP09713736A EP2247592B1 (en) 2008-02-25 2009-02-16 Pyrrolopyrazine kinase inhibitors
PCT/EP2009/051757 WO2009106442A1 (en) 2008-02-25 2009-02-16 Pyrrolopyrazine kinase inhibitors

Publications (1)

Publication Number Publication Date
PL2247592T3 true PL2247592T3 (pl) 2012-01-31

Family

ID=40514094

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09713736T PL2247592T3 (pl) 2008-02-25 2009-02-16 Pirolopirazynowe inhibitory kinazy

Country Status (20)

Country Link
US (1) US7939531B2 (pl)
EP (1) EP2247592B1 (pl)
JP (1) JP5368485B2 (pl)
KR (1) KR101261514B1 (pl)
CN (1) CN101939324B (pl)
AR (1) AR070468A1 (pl)
AT (1) ATE522535T1 (pl)
AU (1) AU2009218607B2 (pl)
BR (1) BRPI0908494A2 (pl)
CA (1) CA2713710A1 (pl)
CL (1) CL2009000406A1 (pl)
DK (1) DK2247592T3 (pl)
IL (1) IL206358A0 (pl)
MX (1) MX2010008198A (pl)
PE (1) PE20091493A1 (pl)
PL (1) PL2247592T3 (pl)
PT (1) PT2247592E (pl)
RU (1) RU2503676C2 (pl)
TW (1) TWI380987B (pl)
WO (1) WO2009106442A1 (pl)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2713718A1 (en) * 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
CN101952295B (zh) * 2008-02-25 2013-11-20 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
ATE517107T1 (de) * 2008-02-25 2011-08-15 Hoffmann La Roche Pyrrolopyrazinkinaseinhibitoren
PT2250172E (pt) * 2008-02-25 2011-11-30 Hoffmann La Roche Inibidores de pirrolpirazina-cinase
HUE028347T2 (en) * 2008-06-10 2016-12-28 Abbvie Inc Tricyclic compounds
MX2011004953A (es) 2008-11-10 2011-12-14 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
GEAP202213376A (en) 2009-06-17 2022-02-25 Vertex Pharmaceuticals Incorporated Us Inhibitors of influenza viruses replication
RU2538204C2 (ru) * 2009-09-10 2015-01-10 Ф.Хоффманн-Ля Рош Аг Ингибиторы jak
KR20120102724A (ko) 2009-12-01 2012-09-18 아보트 러보러터리즈 신규한 트리사이클릭 화합물
ME02800B (me) 2009-12-01 2018-01-20 Abbvie Inc Nova triciklična jedinjenja
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US20130045992A1 (en) 2010-01-28 2013-02-21 President And Fellows Of Harvard College Compositions and Methods for Enhancing Proteasome Activity
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
US8481541B2 (en) * 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
NZ603478A (en) 2010-05-12 2014-09-26 Vertex Pharma 2 -aminopyridine derivatives useful as inhibitors of atr kinase
EP2569286B1 (en) 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2011143419A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
EP2569313A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
KR20130083387A (ko) 2010-05-20 2013-07-22 에프. 호프만-라 로슈 아게 Syk 및 jak 억제제로서 피롤로피라진 유도체
KR20130083386A (ko) * 2010-05-20 2013-07-22 에프. 호프만-라 로슈 아게 피롤로[2,3-ｂ]피라진-7-카복스아마이드 유도체 및 ＪＡＫ 및 ＳＹＫ 억제제로서의 그의 용도
NZ603644A (en) * 2010-05-24 2014-10-31 Univ Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
EP2585468A1 (en) 2010-06-23 2013-05-01 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
AU2012240030A1 (en) 2011-04-05 2013-10-24 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of TRA kinase
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
AU2012255792A1 (en) * 2011-05-17 2013-11-07 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
EP2723747A1 (en) * 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
NZ619699A (en) * 2011-07-05 2016-03-31 Vertex Pharma Processes and intermediates for producing azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
CN104024258B (zh) * 2011-09-01 2017-02-15 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
EP2763990B1 (en) * 2011-09-01 2017-02-22 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
CA2850564A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP3878851A1 (en) 2011-09-30 2021-09-15 Vertex Pharmaceuticals Incorporated Process for making compounds useful as inhibitors of atr kinase
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
RU2018108589A (ru) 2011-09-30 2019-02-25 Вертекс Фармасьютикалз Инкорпорейтед Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2773645A1 (en) 2011-11-01 2014-09-10 F.Hoffmann-La Roche Ag Imidazopyridazine compounds
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
JP2015502925A (ja) 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776429A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013104573A1 (en) 2012-01-10 2013-07-18 F. Hoffmann-La Roche Ag Pyridazine amide compounds and their use as syk inhibitors
PT2833973T (pt) 2012-04-05 2017-12-21 Vertex Pharma Compostos úteis como inibidores da cinase atr e terapias de combinação dos mesmos
EP2888262B1 (en) * 2012-08-21 2018-12-19 F.Hoffmann-La Roche Ag Pyrrolo[2,3-b]pyrazines as syk inhibitors
AU2013312296B2 (en) 2012-09-10 2017-06-22 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
SG11201503977PA (en) 2012-11-20 2015-06-29 Principia Biopharma Inc Azaindole derivatives as jak3 inhibitors
EP2925319B1 (en) 2012-11-30 2019-01-09 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
WO2014089379A1 (en) 2012-12-07 2014-06-12 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
KR20160007581A (ko) * 2013-05-14 2016-01-20 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피리딘- 또는 피라진-함유 화합물
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
HUE052178T2 (hu) 2013-11-13 2021-04-28 Vertex Pharma Eljárások influenzavírus-replikáció inhibitorainak elõállítására
US20160376375A1 (en) 2013-11-27 2016-12-29 Baylor College Of Medicine CSGP4 - Specific Chimeric Antigen Receptor for Cancer
CN103665803B (zh) * 2013-12-05 2015-07-01 湖南大学 一种基于金属环钯化合物的结晶聚乳酸及其制备方法和金属环钯化合物的应用
WO2015085132A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
KR20160117614A (ko) 2014-02-21 2016-10-10 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
HRP20200186T1 (hr) 2014-06-05 2020-05-29 Vertex Pharmaceuticals Inc. Radioaktivno obilježeni derivati 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-karboksamid spojeva koji se koriste kao inhibitori atr kinaze, priprava navedenih spojeva i njihovi različiti čvrsti oblici
JP6936007B2 (ja) 2014-06-17 2021-09-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
US20160002248A1 (en) * 2014-07-03 2016-01-07 Board Of Regents, The University Of Texas System Gls1 inhibitors for treating disease
CN107074805B (zh) 2014-07-03 2021-02-26 德州大学系统董事会 用于治疗疾病的gls1抑制剂
EA036269B1 (ru) 2014-12-18 2020-10-21 Принсипиа Биофарма Инк. Лечение пузырчатки
ES2928757T3 (es) * 2015-05-01 2022-11-22 Pfizer Acrilamidas de pirrolo[2,3-b]pirazinilo y epóxidos de las mismas como inhibidores de la Janus Quinasa
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
WO2016210165A1 (en) 2015-06-24 2016-12-29 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3316887B1 (en) * 2015-06-30 2020-04-08 Board of Regents, The University of Texas System Gls1 inhibitors for treating disease
EP3355926B1 (en) 2015-09-30 2025-12-24 Vertex Pharmaceuticals Inc. Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using
US20170100396A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
KR20250010141A (ko) 2015-10-16 2025-01-20 애브비 인코포레이티드 (3S,4R)-3-에틸-4-(3H-이미다조[1,2-a]피롤로[2,3-e]-피라진-8-일)-N-(2,2,2-트리플루오로에틸)피롤리딘-1-카복스아미드및 이의 고체상 형태의 제조 방법
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
BR112018012660B1 (pt) 2015-12-22 2023-12-19 Board Of Regents, The University Of Texas System Sal, solvato, ou polimorfo de um composto; polimorfo de composto sólido; composição; e uso de um sal, solvato ou polimorfo
EP3478273A1 (en) 2016-06-29 2019-05-08 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2018177993A1 (de) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Pyrazole zur bekämpfung von arthropoden
US10722487B2 (en) 2017-10-18 2020-07-28 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
CN112105359B (zh) * 2017-12-04 2023-12-01 豪夫迈·罗氏有限公司 作为cccDNA抑制剂用于治疗乙型肝炎病毒(HBV)感染的吡咯并[2,3-b]吡嗪化合物
EP3735411B1 (en) * 2018-01-05 2024-07-10 AC Immune SA 1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer`s disease
EP3994142A4 (en) * 2019-07-03 2023-09-06 Borah, Inc. CHEMICAL COMPOUNDS
EP4045051A1 (en) 2019-10-14 2022-08-24 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
CN115087655A (zh) 2019-12-20 2022-09-20 辉瑞公司 苯并咪唑衍生物
PH12022551787A1 (en) 2020-01-22 2024-02-12 Principia Biopharma Inc Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2023025109A1 (zh) * 2021-08-23 2023-03-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用
EP4644396A1 (en) * 2022-12-28 2025-11-05 Visionpharma (Nantong) Co., Ltd Toll-like receptor inhibitor, and preparation therefor and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW505646B (en) * 1998-06-19 2002-10-11 Pfizer Prod Inc Pyrrolo [2,3-d] pyrimidine compounds
WO2001047922A2 (en) * 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
KR20040111445A (ko) * 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
US20070066641A1 (en) * 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
CN1925855B (zh) * 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
BRPI0513899A (pt) * 2004-07-27 2008-05-20 Sgx Pharmaceuticals Inc moduladores de cinase heterocìclica de anel fundido
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
EP1814883A1 (en) * 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
WO2007015866A2 (en) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
CL2007002617A1 (es) 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA

Also Published As

Publication number Publication date
CL2009000406A1 (es) 2010-09-21
JP2011513262A (ja) 2011-04-28
RU2010139566A (ru) 2012-04-10
IL206358A0 (en) 2010-12-30
TW200938547A (en) 2009-09-16
DK2247592T3 (da) 2011-09-26
TWI380987B (zh) 2013-01-01
CA2713710A1 (en) 2009-09-03
AR070468A1 (es) 2010-04-07
WO2009106442A1 (en) 2009-09-03
ATE522535T1 (de) 2011-09-15
MX2010008198A (es) 2010-08-23
RU2503676C2 (ru) 2014-01-10
US20090215750A1 (en) 2009-08-27
BRPI0908494A2 (pt) 2015-08-11
AU2009218607B2 (en) 2014-02-13
AU2009218607A1 (en) 2009-09-03
CN101939324A (zh) 2011-01-05
PT2247592E (pt) 2011-11-03
PE20091493A1 (es) 2009-09-25
EP2247592B1 (en) 2011-08-31
EP2247592A1 (en) 2010-11-10
KR101261514B1 (ko) 2013-05-07
JP5368485B2 (ja) 2013-12-18
KR20100114094A (ko) 2010-10-22
US7939531B2 (en) 2011-05-10
CN101939324B (zh) 2014-10-15

Similar Documents

Publication Publication Date Title
IL206358A0 (en) Pyrrolopyrazine kinase inhibitors
IL206818A0 (en) Pyrrolopyrazine kinase inhibitors
HUS1900014I1 (hu) Proteinkináz inhibitorok
ZA201102423B (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
ZA201008808B (en) Novel phenylpyrazinones as kinase inhibitors
IL209258A0 (en) Pyrrolopyridines as kinase inhibitors
ZA201204246B (en) Kinase inhibitors
ZA201203842B (en) Kinase inhibitors
IL220212A0 (en) Aminopyrimidine kinase inhibitors
IL213464A0 (en) Kinase inhibitor compounds
ZA201107717B (en) Imidazopyrazines for use kinase inhibitors
IL212499A0 (en) Pyrrolopyrazinyl urea kinase inhibitors
PL2231642T3 (pl) Pirymidyny jako inhibitory kinazy
IL210073A0 (en) Protein kinase inhibitors
IL210573A0 (en) Compounds as kinase inhibitors
IL210069A0 (en) Protein kinase inhibitors
ZA201008878B (en) Naphthyridiniones as aurora kinase inhibitors
EP2247185A4 (en) INHIBITORS OF TYROSINE KINASE
ZA200908943B (en) Pyrazolopyrimidinone kinase inhibitor
GB0914726D0 (en) Kinase inhibitors
ZA201004903B (en) Pyrrolopyrazine kinase inhibitors
GB0807642D0 (en) IKK- serine-threonine protein kinase inhibitors